Universitätsklinik
für Innere Medizin V Innsbruck

(Schwerpunkte: Hämatologie und Internistische Onkologie)
Medizinische Universität Innsbruck

Home > Studien > Studien Onkologie

OFFEN

Erkankung              Akronym/Sponsor                  PatientInnengruppe                             Local PI

NSCLC                     PEARLS (Keynote 091)              Post-op, +/-adj. Chemoth                       OA Dr. Pall

Pankreas                  ABCSGP02                               loc. advanced, inop., neoadj.                   OÄ. Dr.in Djanani

NSCLC                     Hudson                                    Biomarker-driven therapy bei                  PD. Dr. Pircher

                                                                             IO-Resistenz 

 

IN BÄLDE OFFEN:

NSCLC                     Keynote 867                             Inop. St I+IIA                                        OA Dr. Pall

NSCLC                     MSD                                        1st Line St IV NSCLC/Pembro+Taxol         OA Dr. Pall

                                                                             gefolgt  von Pembro +/- Olaparib Maint.

NSCLC                     MSD                                        1st Line St IV NSCLC/Pembro+Platin         OA Dr. Pall

                                                                             Pembro+Olaparib vs Pemetrex Maint.

NSCLC KRASmut           AMG510                                   KRASmut-specific mAb                              OA Dr. Pall

Met. CRC                Solstice                                     1st Line Lonsurf/Beva vs Cape/Beva         OA Dr. Amann

 

Universitätsklinik für Innere Medizin V Innsbruck | Anichstrasse 35, A-6020 Innsbruck | Tel.: +43 (0)512/504-24003 , Fax: +43 (0)512/504-25615